首页> 美国卫生研究院文献>PLoS Clinical Trials >Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs
【2h】

Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs

机译:未开发物种的药物发现前景:批准的天然产物药物的指示

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Due to extensive bioprospecting efforts of the past and technology factors, there have been questions about drug discovery prospect from untapped species. We analyzed recent trends of approved drugs derived from previously untapped species, which show no sign of untapped drug-productive species being near extinction and suggest high probability of deriving new drugs from new species in existing drug-productive species families and clusters. Case histories of recently approved drugs reveal useful strategies for deriving new drugs from the scaffolds and pharmacophores of the natural product leads of these untapped species. New technologies such as cryptic gene-cluster exploration may generate novel natural products with highly anticipated potential impact on drug discovery.
机译:由于过去生物勘探的广泛努力和技术因素,对于未开发物种的药物发现前景存在疑问。我们分析了以前未开发物种的已批准药物的最新趋势,这些趋势未显示未开发药物生产的物种濒临灭绝的迹象,并暗示从现有药物生产物种家族和集群的新物种中获得新药物的可能性很高。最近批准的药物的病史揭示了从这些未开发物种的天然产物先导的支架和药效基团衍生新药物的有用策略。诸如秘密基因簇探索之类的新技术可能会产生对药物发现具有高度预期潜在影响的新型天然产物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号